$CLCS
Cell Source, Inc. Stock $clcs

$clcs Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-K Financial Statement

#000149315223027069 Filed on August 08, 2023

Income Statement

Concept	2023 Q3	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$480.0K	$607.6K	$2.179M
YoY Change	-10.03%	68.1%	-19.15%
% of Gross Profit
Research & Development	$510.0K	$465.2K	$1.938M
YoY Change	8.97%	97.3%	46.45%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$995.4K	$1.073M	$4.175M
YoY Change	-2.03%	82.82%	3.9%
Operating Profit	-$995.4K		-$4.175M
YoY Change	-2.03%		3.9%
Interest Expense	-$340.0K	-$264.5K	-$992.4K
YoY Change	43.91%	70.87%	-27.07%
% of Operating Profit
Other Income/Expense, Net	-$342.8K		-$992.4K
YoY Change	45.07%		-31.74%
Pretax Income	-$1.340M	-$1.337M	-$5.168M
YoY Change	7.0%	60.15%	-5.57%
Income Tax
% Of Pretax Income
Net Earnings	-$1.338M	-$1.625M	-$5.168M
YoY Change	6.85%	94.61%	-5.56%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.04		-$0.18
Diluted Earnings Per Share	-$0.04	-$0.05	-$0.18
COMMON SHARES
Basic Shares Outstanding	38.16M shares	35.25M shares	34.84M shares
Diluted Shares Outstanding	38.19M shares		34.84M shares

Balance Sheet

Concept	2023 Q3	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$0.00	$222.7K	$222.7K
YoY Change	-100.0%	139.17%	139.17%
Cash & Equivalents	$2.582K	$222.7K
Short-Term Investments
Other Short-Term Assets	$3.400K	$23.01K	$187.2K
YoY Change	-83.29%	-89.57%	-15.17%
Inventory
Prepaid Expenses	$242.4K	$164.2K
Receivables
Other Receivables
Total Short-Term Assets	$250.0K	$409.9K	$409.9K
YoY Change	-30.67%	30.62%	30.62%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	-$1.643K	-$5.00	$0.00
YoY Change	-164400.0%
TOTAL ASSETS
Total Short-Term Assets	$250.0K	$409.9K	$409.9K
Total Long-Term Assets	-$1.643K	-$5.00	$0.00
Total Assets	$248.4K	$409.8K	$409.9K
YoY Change	-31.13%	30.62%	30.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.581M	$680.3K	$680.3K
YoY Change	134.47%	205.02%	205.03%
Accrued Expenses	$4.550M	$1.486M	$4.219M
YoY Change	254.19%	-52.34%	35.34%
Deferred Revenue
YoY Change
Short-Term Debt	$680.0K	$768.1K	$768.1K
YoY Change	-10.54%	1.08%	1.08%
Long-Term Debt Due	$1.480M	$1.058M	$1.058M
YoY Change	72.46%	-46.67%	-46.67%
Total Short-Term Liabilities	$16.28M	$13.04M	$13.04M
YoY Change	32.2%	28.64%	28.64%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.28M	$13.04M	$13.04M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$16.28M	$13.04M	$13.04M
YoY Change	32.19%	28.64%	28.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$40.62M	-$36.35M
YoY Change	16.02%	16.57%
Common Stock	$38.50K	$36.08K
YoY Change	9.22%	5.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$16.03M	-$12.63M	-$12.63M
YoY Change
Total Liabilities & Shareholders Equity	$248.4K	$409.8K	$409.9K
YoY Change	-31.13%	30.62%	30.62%

Cashflow Statement

Concept	2023 Q3	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$1.338M	-$1.625M	-$5.168M
YoY Change	6.85%	94.61%	-5.56%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$280.0K	-$723.3K	-$3.139M
YoY Change	-74.23%	57.51%	-7.09%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	270.0K	880.0K	$3.268M
YoY Change	-76.52%	-1966.38%	1.29%
NET CHANGE
Cash From Operating Activities	-280.0K	-723.3K	-$3.139M
Cash From Investing Activities
Cash From Financing Activities	270.0K	880.0K	$3.268M
Net Change In Cash	-10.00K	156.7K	$129.6K
YoY Change	-115.79%	-130.95%	-185.23%
FREE CASH FLOW
Cash From Operating Activities	-$280.0K	-$723.3K	-$3.139M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001569340
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	CLCS	Gain On Forgiveness Of Accrued Interest GainOnForgivenessOfAccruedInterest		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2021	CLCS	Conversion Of Series C Convertible Preferred Stock Into Common Stock ConversionOfSeriesCConvertiblePreferredStockIntoCommonStock		usd
CY2022	CLCS	Gain On Forgiveness Of Accrued Interest GainOnForgivenessOfAccruedInterest		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	CLCS	Warrant Modification Expense WarrantModificationExpense		usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
CY2022	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt		usd
CY2022	CLCS	Series C Convertible Preferred Stock Issued In Connection With Loss On Extinguishment Of Notes Payable SeriesCConvertiblePreferredStockIssuedInConnectionWithLossOnExtinguishmentOfNotesPayable		usd
CY2022	CLCS	Conversion Of Convertible Preferred Stock Into Common Stock ConversionOfConvertiblePreferredStockIntoCommonStock		usd
CY2022	CLCS	Issuance Of Common Stock Pursuant To Cashless Warrant Exercise IssuanceOfCommonStockPursuantToCashlessWarrantExercise		usd
CY2022	CLCS	Common Stock Issued In Satisfaction Of Accrued Compensation CommonStockIssuedInSatisfactionOfAccruedCompensation		usd
CY2022	CLCS	Financing Of Directors And Officers Insurance FinancingOfDirectorsAndOfficersInsurance		usd
CY2022	CLCS	Accrued Interest Converted Into Notes Payable AccruedInterestConvertedIntoNotesPayable		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		usd
CY2022Q4	CLCS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-55413
CY2022	dei	Entity Registrant Name EntityRegistrantName	Cell Source, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	32-0379665
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	57 West 57th Street
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 400
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10019
CY2022	dei	City Area Code CityAreaCode	(646)
CY2022	dei	Local Phone Number LocalPhoneNumber	416-7896
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	17982012	usd
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	38163385	shares
CY2022	dei	Auditor Firm AuditorFirmId	688
CY2022	dei	Auditor Name AuditorName	Marcum
CY2022	dei	Auditor Location AuditorLocation	New York, NY
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	222665	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	93095	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	164175	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	203750	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	23005	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	16922	usd
CY2022Q4	us-gaap	Assets Assets	409845	usd
CY2021Q4	us-gaap	Assets Assets	313767	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	680325	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	223041	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1485857	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1097021	usd
CY2022Q4	CLCS	Accrued Expenses Related Parties Current AccruedExpensesRelatedPartiesCurrent	86500	usd
CY2021Q4	CLCS	Accrued Expenses Related Parties Current AccruedExpensesRelatedPartiesCurrent	72000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	809426	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	725308	usd
CY2022Q4	CLCS	Accrued Interest Related Parties Current AccruedInterestRelatedPartiesCurrent	987310	usd
CY2021Q4	CLCS	Accrued Interest Related Parties Current AccruedInterestRelatedPartiesCurrent	456917	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	849898	usd
CY2021Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	766102	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	768126	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	759912	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	150000	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	150000	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	908311	usd
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1834446	usd
CY2022Q4	CLCS	Convertible Notes Payable Related Parties Current ConvertibleNotesPayableRelatedPartiesCurrent	6077770	usd
CY2021Q4	CLCS	Convertible Notes Payable Related Parties Current ConvertibleNotesPayableRelatedPartiesCurrent	3725000	usd
CY2022Q4	CLCS	Advances Payable Current AdvancesPayableCurrent	135000	usd
CY2021Q4	CLCS	Advances Payable Current AdvancesPayableCurrent	135000	usd
CY2022Q4	CLCS	Advances Payable Related Party Current AdvancesPayableRelatedPartyCurrent	100000	usd
CY2021Q4	CLCS	Advances Payable Related Party Current AdvancesPayableRelatedPartyCurrent	100000	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	27926	usd
CY2022Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	5217	usd
CY2021Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	67229	usd
CY2022Q4	us-gaap	Liabilities Liabilities	13043740	usd
CY2021Q4	us-gaap	Liabilities Liabilities	10139902	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36081758	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36081758	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34360546	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34360546	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	36082	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	34361	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	23674354	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	21316318	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36346176	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-31178428	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-12633895	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-9826135	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	409845	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	313767	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1938173	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1273352	usd
CY2022	CLCS	Research And Development Related Party ResearchAndDevelopmentRelatedParty	58000	usd
CY2021	CLCS	Research And Development Related Party ResearchAndDevelopmentRelatedParty	50056	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2179160	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2695164	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	4175333	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	4018572	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-4175333	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-4018572	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	170868	usd
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	380230	usd
CY2022	CLCS	Interest Expense Related Parties InterestExpenseRelatedParties	536247	usd
CY2021	CLCS	Interest Expense Related Parties InterestExpenseRelatedParties	248971	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	136356	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	408619	usd
CY2022	CLCS	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty	148944	usd
CY2021	CLCS	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty	322883	usd
CY2021	CLCS	Gain On Forgiveness Of Accrued Interest GainOnForgivenessOfAccruedInterest	49983	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-143143	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-992415	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1453863	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5167748	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-5472435	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1157486	usd
CY2021	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	973205	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6325234	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6445640	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34836169	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34836169	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33116729	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33116729	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-7947382	usd
CY2021	CLCS	Conversion Of Convertible Notes Payable And Accrued Interest Into Series C Convertible Preferred Stock And Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertiblePreferredStockAndCommonStock	2145641	usd
CY2021	CLCS	Stock Issued During Convertible Preferred Stock And Warrants Issued In Connection With Loss On Extinguishment Of Notes Payable StockIssuedDuringConvertiblePreferredStockAndWarrantsIssuedInConnectionWithLossOnExtinguishmentOfNotesPayable	143425	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	-973205	usd
CY2021	us-gaap	Dividends Preferred Stock Paidinkind DividendsPreferredStockPaidinkind	931186	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	480195	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	139728	usd
CY2021	CLCS	Warrants Issued In Satisfaction Of Accrued Interest WarrantsIssuedInSatisfactionOfAccruedInterest	247566	usd
CY2021	CLCS	Warrants Modification Expense WarrantsModificationExpense	29000	usd
CY2021	CLCS	Common Stock Value Issued In Satisfaction Of Accrued Compensation CommonStockValueIssuedInSatisfactionOfAccruedCompensation	7097	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	73040	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	206400	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	163609	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-5472435	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-9826135	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-9826135	usd
CY2022	CLCS	Conversion Of Convertible Notes Payable And Accrued Interest Into Series C Convertible Preferred Stock And Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertiblePreferredStockAndCommonStock	1802109	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	-1157486	usd
CY2022	us-gaap	Dividends Preferred Stock Paidinkind DividendsPreferredStockPaidinkind	1219498	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	242183	usd
CY2022	CLCS	Warrants Issued In Satisfaction Of Accrued Interest WarrantsIssuedInSatisfactionOfAccruedInterest	173712	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	5372	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	74600	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5167748	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-12633895	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-12633895	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5167748	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-5472435	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	285300	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	731502	usd
CY2021	CLCS	Gain On Forgiveness Of Accrued Interest GainOnForgivenessOfAccruedInterest	49983	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-143143	usd
CY2021	CLCS	Warrant Modification Expense WarrantModificationExpense	29000	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	102355	usd
CY2021	us-gaap	Other Noncash Expense OtherNoncashExpense	119450	usd
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	74600	usd
CY2021	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	206400	usd
CY2022	CLCS	Warrants Based Compensation WarrantsBasedCompensation	4832	usd
CY2021	CLCS	Warrants Based Compensation WarrantsBasedCompensation	160045	usd
CY2022	CLCS	Common Stock Based Compensation CommonStockBasedCompensation	-1545	usd
CY2021	CLCS	Common Stock Based Compensation CommonStockBasedCompensation	52956	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-39575	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-294319	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	6083	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-12729	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	457284	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	29946	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	388836	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-62929	usd
CY2022	CLCS	Increase Decrease In Accrued Liabilities Related Parties IncreaseDecreaseInAccruedLiabilitiesRelatedParties	14500	usd
CY2021	CLCS	Increase Decrease In Accrued Liabilities Related Parties IncreaseDecreaseInAccruedLiabilitiesRelatedParties	-126701	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	111861	usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	270964	usd
CY2022	CLCS	Increase Decrease In Accrued Interest Related Parties IncreaseDecreaseInAccruedInterestRelatedParties	471666	usd
CY2021	CLCS	Increase Decrease In Accrued Interest Related Parties IncreaseDecreaseInAccruedInterestRelatedParties	210250	usd
CY2022	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	85881	usd
CY2021	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	72662	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3138686	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3378682	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	775000	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2407820	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	2500000	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1500000	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	168094	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	146912	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	203088	usd
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	125000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	27926	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	292574	usd
CY2021	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	60500	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3268256	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3226658	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	129570	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-152024	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	93095	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	245119	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	222665	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	93095	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	19898	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	20768	usd
CY2022	CLCS	Accrual Of Earned Preferred Stock Dividends AccrualOfEarnedPreferredStockDividends	-1157486	usd
CY2021	CLCS	Accrual Of Earned Preferred Stock Dividends AccrualOfEarnedPreferredStockDividends	-973205	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	1219498	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	931186	usd
CY2022	CLCS	Conversion Of Convertible Notes Payable And Accrued Interest Into Series C Preferred Stock And Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCPreferredStockAndCommonStock	1802109	usd
CY2021	CLCS	Conversion Of Convertible Notes Payable And Accrued Interest Into Series C Preferred Stock And Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCPreferredStockAndCommonStock	2145641	usd
CY2021	CLCS	Series C Convertible Preferred Stock Issued In Connection With Loss On Extinguishment Of Notes Payable SeriesCConvertiblePreferredStockIssuedInConnectionWithLossOnExtinguishmentOfNotesPayable	143425	usd
CY2021	CLCS	Conversion Of Convertible Preferred Stock Into Common Stock ConversionOfConvertiblePreferredStockIntoCommonStock	150	usd
CY2021	CLCS	Issuance Of Common Stock Pursuant To Cashless Warrant Exercise IssuanceOfCommonStockPursuantToCashlessWarrantExercise	125	usd
CY2021	CLCS	Common Stock Issued In Satisfaction Of Accrued Compensation CommonStockIssuedInSatisfactionOfAccruedCompensation	7097	usd
CY2021	CLCS	Financing Of Directors And Officers Insurance FinancingOfDirectorsAndOfficersInsurance	320500	usd
CY2021	CLCS	Accrued Interest Converted Into Notes Payable AccruedInterestConvertedIntoNotesPayable	41950	usd
CY2022	CLCS	Issuance Of Warrants In Connection With Issuance Of Notes Payable IssuanceOfWarrantsInConnectionWithIssuanceOfNotesPayable	242183	usd
CY2021	CLCS	Issuance Of Warrants In Connection With Issuance Of Notes Payable IssuanceOfWarrantsInConnectionWithIssuanceOfNotesPayable	480195	usd
CY2022	CLCS	Issuance Of Warrants In Satisfaction Of Accrued Interest IssuanceOfWarrantsInSatisfactionOfAccruedInterest	173712	usd
CY2021	CLCS	Issuance Of Warrants In Satisfaction Of Accrued Interest IssuanceOfWarrantsInSatisfactionOfAccruedInterest	247566	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5168000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-5472000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3139000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3379000	usd
CY2022Q4	CLCS	Working Capital Surplus Deficiency WorkingCapitalSurplusDeficiency	12634000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36346000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_z2mvExViFNxk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zGYqGNPqZzKb">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. Management bases its estimates and judgements on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, and stock-based compensation. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of any material revisions are reflected in the consolidated financial statements in the period that they are determined to be necessary. See the <i>Stock-Based Compensation</i> section of this footnote for additional discussion of the use of estimates in estimating the fair value of the Company’s common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	19898	usd
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	20768	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	41400494	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	35602172	shares
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.75
CY2021Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.75
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zUL6iVVzTQad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86E_znXfPnJ54sr1">Reclassifications</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period balances have been reclassified in order to conform to current year presentation. These reclassifications have no effect on previously reported results of operations or loss per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2020Q4	CLCS	Fair Value Inputs Measured On Recurring Basis Beginning Balance FairValueInputsMeasuredOnRecurringBasisBeginningBalance	624789	usd
CY2021	CLCS	Fair Value Assets Measured On Recurring Basis Changes In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangesInUnrealizedGainLoss	-78430	usd
CY2021	CLCS	Accrued Interest Warrant One AccruedInterestWarrantOne	164857	usd
CY2021	CLCS	Issuance Of Warrants IssuanceOfWarrants	-247566	usd
CY2021Q4	CLCS	Fair Value Inputs Measured On Recurring Basis Beginning Balance FairValueInputsMeasuredOnRecurringBasisBeginningBalance	463650	usd
CY2022	CLCS	Fair Value Assets Measured On Recurring Basis Changes In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangesInUnrealizedGainLoss	100270	usd
CY2022	CLCS	Accrued Interest Warrant One AccruedInterestWarrantOne	173712	usd
CY2022	CLCS	Issuance Of Warrants IssuanceOfWarrants	-173712	usd
CY2022Q4	CLCS	Fair Value Inputs Measured On Recurring Basis Ending Balance FairValueInputsMeasuredOnRecurringBasisEndingBalance	563920	usd
CY2021	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	154495	shares
CY2022	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	154495	shares
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	50983	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	52528	usd
CY2022Q4	CLCS	Accrued Research And Development AccruedResearchAndDevelopment	516516	usd
CY2021Q4	CLCS	Accrued Research And Development AccruedResearchAndDevelopment	596773	usd
CY2022Q4	CLCS	Accrued Third Party Payments AccruedThirdPartyPayments	6347	usd
CY2021Q4	CLCS	Accrued Third Party Payments AccruedThirdPartyPayments	4816	usd
CY2022Q4	CLCS	Accrued Legal Fees AccruedLegalFees	198154	usd
CY2021Q4	CLCS	Accrued Legal Fees AccruedLegalFees	118687	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	719028	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	336517	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9750	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9750	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	36062	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	30478	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1485857	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1097021	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	127963	usd
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	124718	usd
CY2022Q4	CLCS	Accrued Social Security Current AccruedSocialSecurityCurrent	77266	usd
CY2021Q4	CLCS	Accrued Social Security Current AccruedSocialSecurityCurrent	40616	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	50983	usd
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	52528	usd
CY2022Q4	CLCS	Stockbased Compensation Warrants StockbasedCompensationWarrants	8237	usd
CY2021Q4	CLCS	Stockbased Compensation Warrants StockbasedCompensationWarrants	8777	usd
CY2022Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	254736	usd
CY2021Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	241733	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	88644	usd
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	88753	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	77429	usd
CY2021Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	65898	usd
CY2022Q4	CLCS	Accrued Severance Current AccruedSeveranceCurrent	164640	usd
CY2021Q4	CLCS	Accrued Severance Current AccruedSeveranceCurrent	143079	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	849898	usd
CY2021Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	766102	usd
CY2022	CLCS	Repayment Of Advances Payable RepaymentOfAdvancesPayable	0	usd
CY2021	CLCS	Repayment Of Advances Payable RepaymentOfAdvancesPayable	60500	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	1408000	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	2046053	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	768126	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	759912	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	150000	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	150000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	908311	usd
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1834446	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	6077770	usd
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	3725000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	247500	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.75
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	14326	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	41106	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-4444646	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-4957487	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-723102	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-514947	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5167748	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5472434	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-669697	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-994748	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	303995	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-118438	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-388958	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-658716	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-754660	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1771902	usd
CY2022	CLCS	Income Tax Expense Benefit Valuation Allowance IncomeTaxExpenseBenefitValuationAllowance	-754660	usd
CY2021	CLCS	Income Tax Expense Benefit Valuation Allowance IncomeTaxExpenseBenefitValuationAllowance	-1771902	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.112	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.118	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.003	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.002	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.047	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.000	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.132	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.006	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.146	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.324	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9071868	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8950435	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	589959	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	539058	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	609079	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	26753	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10270906	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	9516246	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10270906	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9516246	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	17800000	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	16000000	usd
CY2022Q4	CLCS	Operating Loss Carryforwards Subject To Expiration OperatingLossCarryforwardsSubjectToExpiration	4000000	usd
CY2022Q4	CLCS	Operating Loss Carryforwards Not Subject To Expiration OperatingLossCarryforwardsNotSubjectToExpiration	13800000	usd
CY2021Q4	CLCS	Operating Loss Carryforwards Not Subject To Expiration OperatingLossCarryforwardsNotSubjectToExpiration	12000000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	754660	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1771902	usd
CY2022Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	usd
CY2021Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.75
CY2022Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	251511	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.80
CY2021Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	67230	usd
CY2022Q4	CLCS	Common Stock Accrued Dividend Issued CommonStockAccruedDividendIssued	417944	shares
CY2021Q4	CLCS	Common Stock Accrued Dividend Issued CommonStockAccruedDividendIssued	0	shares
CY2021Q4	CLCS	Additional Accrued Dividend Par Value AdditionalAccruedDividendParValue	0.75
CY2022Q4	CLCS	Additional Accrued Dividend Par Value AdditionalAccruedDividendParValue	0.75
CY2022	CLCS	Accrued Dividend Designation AccruedDividendDesignation	313523	usd
CY2021	CLCS	Accrued Dividend Designation AccruedDividendDesignation	0	usd
CY2022Q4	CLCS	Accrued Dividend Payable AccruedDividendPayable	5217	usd
CY2021Q4	CLCS	Accrued Dividend Payable AccruedDividendPayable	67229	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	77887	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	419401	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	2820000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	3792426	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	11108079	shares
CY2021Q4	CLCS	Share Based Compensation Arrangements By Share Based Payment Award Non Options Weighted Average Exercise Price Outstanding ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceOutstanding	1.02
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	2820000	shares
CY2022	CLCS	Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice	1.21
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	50000	shares
CY2022	CLCS	Share Based Compensation Arrangements By Share Based Payment Award Non Options Expired Cacelled Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredCacelledWeightedAverageExercisePrice	0.75
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	13878079	shares
CY2022Q4	CLCS	Share Based Compensation Arrangements By Share Based Payment Award Non Options Weighted Average Exercise Price Outstanding ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceOutstanding	1.06
CY2022	CLCS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm	P3Y6M
CY2022Q4	CLCS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	13878079	shares
CY2022Q4	CLCS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice	1.06
CY2022	CLCS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm	P3Y6M
CY2021Q1	CLCS	Stock Options To Purchase Common Stock StockOptionsToPurchaseCommonStock	1350000	shares
CY2021Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.00
CY2021Q4	CLCS	Fair Value Of Option FairValueOfOption	218600	usd
CY2022Q3	CLCS	Stock Options To Purchase Common Stock StockOptionsToPurchaseCommonStock	750000	shares
CY2022Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.00
CY2022Q3	CLCS	Fair Value Of Option FairValueOfOption	74600	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.10
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.16
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6182004	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	750000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.00
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6932004	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.83
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y1M6D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6932004	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.83
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y1M6D
CY2019Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	250000	usd
CY2019Q4	us-gaap	Litigation Settlement Amount Awarded From Other Party LitigationSettlementAmountAwardedFromOtherParty	267680	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	146912	usd
CY2022	CLCS	Remaining Amount Due RemainingAmountDue	106000	usd
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	360000	shares

Files In Submission

Name	View Source	Status
0001493152-23-027069-index-headers.html	Edgar Link	pending
0001493152-23-027069-index.html	Edgar Link	pending
0001493152-23-027069.txt	Edgar Link	pending
0001493152-23-027069-xbrl.zip	Edgar Link	pending
clcs-20221231.xsd	Edgar Link	pending
clcs-20221231_cal.xml	Edgar Link	unprocessable
clcs-20221231_lab.xml	Edgar Link	unprocessable
clcs-20221231_def.xml	Edgar Link	unprocessable
clcs-20221231_pre.xml	Edgar Link	unprocessable
ex10-64a.htm	Edgar Link	pending
ex10-64b.htm	Edgar Link	pending
ex10-64c.htm	Edgar Link	pending
ex10-68a.htm	Edgar Link	pending
ex3-5a.htm	Edgar Link	pending
ex3-5a_001.jpg	Edgar Link	pending
ex3-5a_002.jpg	Edgar Link	pending
ex3-6a.htm	Edgar Link	pending
ex3-6a_001.jpg	Edgar Link	pending
ex3-6a_002.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_004.jpg	Edgar Link	pending
form10-k_005.jpg	Edgar Link	pending
form10-k_006.jpg	Edgar Link	pending
form10-k_007.jpg	Edgar Link	pending
form10-k_008.jpg	Edgar Link	pending
form10-k_009.jpg	Edgar Link	pending
form10-k_010.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLCS
Cell Source, Inc. Stock $clcs

2023 Q3 Form 10-K Financial Statement

#000149315223027069 Filed on August 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLCS Cell Source, Inc. Stock $clcs

2023 Q3 Form 10-K Financial Statement

#000149315223027069 Filed on August 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLCS
Cell Source, Inc. Stock $clcs